$TWST

Green Paula sold $25K of TWST

Green Paula (SVP of Human Resources) sold 291 shares of Twist Bioscience Corp (TWST) at $87.32 on 2026-06-22.

Original reporting
SEC EDGAR · Green Paula
Published Jun 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not include guidance, operational updates, or legal/financial events.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosed sale is small and not tied to a corporate catalyst.

03

What to watch

No 10b5-1 plan is indicated, but the filing does not provide intent or context; traders should avoid extrapolating from a single small sale.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-24 after-hours; reflects sale executed 2026-06-22.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed an SVP of Human Resources open-market sale of 291 shares at $87.3224 on 2026-06-22 via Form 4.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a small, single-tranche open-market sale by an HR SVP with no 10b5-1 plan stated; size is modest ($25.4k) and does not indicate a corporate event.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None expected beyond normal US small-cap/biotech sentiment noise.

None expected.

Counterpoint

The sale may be purely personal liquidity (e.g., taxes/financial planning) and not a view on fundamentals, especially given the modest dollar amount.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Green Paula

    SVP of Human Resources who sold 291 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.